Q4 2021 Holdings
Filed 2022-02-11 | 152 holdings | $587.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Beigene LTD(ONC) | SPONSORED ADR | 07725L102 | $182.9M | 675,000 | 31.1% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $175.1M | 500,000 | 29.8% |
| Alnylam Pharmaceuticals Inc(ALNY) | COM | 02043Q107 | $110.2M | 650,000 | 18.8% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $45.6M | 1,000,000 | 7.8% |
| Aurinia Pharmaceuticals Inc(AUPH) | COM | 05156V102 | $22.9M | 1,000,000 | 3.9% |
| ALX Oncology Hldgs Inc(ALXO) | COM | 00166B105 | $10.7M | 500,000 | 1.8% |
| Black Diamond Therapeutics I(BDTX) | COM | 09203E105 | $8.8M | 1,646,517 | 1.5% |
| Adagene Inc(ADAG) | ADS | 005329107 | $8.1M | 1,000,000 | 1.4% |
| Caribou Biosciences Inc(CRBU) | COM | 142038108 | $6.1M | 405,347 | 1.0% |
| Cardiff Oncology Inc(CRDF) | COM | 14147L108 | $4.5M | 750,000 | 0.8% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $4.2M | 250,000 | 0.7% |
| Cullinan Oncology Inc(CGEM) | COM | 230031106 | $3.9M | 250,000 | 0.7% |
| Corvus Pharmaceuticals Inc(CRVS) | COM | 221015100 | $1.2M | 500,000 | 0.2% |
| Lexicon Pharmaceuticals Inc(LXRX) | COM NEW | 528872302 | $280.4K | 71,178,364 | 0.0% |
| WW Intl Inc(WW6) | COM | 98262P101 | $239.0K | 14,818,300 | 0.0% |
| Mirati Therapeutics Inc(MRTXEUR) | COM | 60468T105 | $205.4K | 1,400,000 | 0.0% |
| Spdr SER TR(XBI)Call | S&P BIOTECH | 78464A870 | $112.0K | 1,000,000 | 0.0% |
| Seer Inc(SEER) | COM CL A | 81578P106 | $108.3K | 4,750,000 | 0.0% |
| Fate Therapeutics Inc(FATE) | COM | 31189P102 | $105.3K | 1,800,000 | 0.0% |
| Seagen Inc(SGENUSD) | COM | 81181C104 | $77.3K | 500,000 | 0.0% |
| Morphic Hldg Inc | COM | 61775R105 | $75.1K | 1,585,049 | 0.0% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $69.3K | 6,000,000 | 0.0% |
| Bellus Health Inc New(BLU) | COM NEW | 07987C204 | $68.4K | 8,500,000 | 0.0% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $63.5K | 1,000,000 | 0.0% |
| Bristol-Myers Squibb Co(BMY)Call | COM | 110122108 | $62.4K | 1,000,000 | 0.0% |
| Scholar Rock Hldg Corp(SRRK) | COM | 80706P103 | $60.9K | 2,450,000 | 0.0% |
| Citigroup Inc(C)Call | COM NEW | 172967424 | $60.4K | 1,000,000 | 0.0% |
| Springworks Therapeutics Inc | COM | 85205L107 | $52.7K | 850,000 | 0.0% |
| Erasca Inc(ERAS) | COM | 29479A108 | $49.4K | 3,172,221 | 0.0% |
| Krystal Biotech Inc(KRYS) | COM | 501147102 | $49.0K | 700,000 | 0.0% |
| Cerevel Therapeutics Hldng I(CERE1EUR) | COM | 15678U128 | $48.6K | 1,500,000 | 0.0% |
| IGM Biosciences Inc(1K0) | COM | 449585108 | $44.0K | 1,500,000 | 0.0% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $42.8K | 1,250,000 | 0.0% |
| Sage Therapeutics Inc(SG7) | COM | 78667J108 | $42.5K | 1,000,000 | 0.0% |
| I MAB(NBP) | SPONSORED ADS | 44975P103 | $40.3K | 850,000 | 0.0% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $39.4K | 1,720,720 | 0.0% |
| Rubius Therapeutics Inc | COM | 78116T103 | $35.8K | 3,701,580 | 0.0% |
| Intellia Therapeutics Inc(NTLA) | COM | 45826J105 | $32.5K | 275,000 | 0.0% |
| Talaris Therapeutics Inc | COM | 87410C104 | $31.6K | 2,064,262 | 0.0% |
| Allovir Inc | COM | 019818103 | $30.1K | 2,323,371 | 0.0% |
| Evotec AG(EVO) | SPONSORED ADS | 30050E105 | $27.3K | 1,149,425 | 0.0% |
| Eqrx Inc | COM | 26886C107 | $27.3K | 4,000,000 | 0.0% |
| Denali Therapeutics Inc(DNLI) | COM | 24823R105 | $26.8K | 600,000 | 0.0% |
| Gossamer BIO Inc(GOSS) | COM | 38341P102 | $26.7K | 2,358,968 | 0.0% |
| Omega Therapeutics Inc | COMMON STOCK | 68217N105 | $25.8K | 2,273,530 | 0.0% |
| Iteos Therapeutics Inc(5E7) | COM | 46565G104 | $25.3K | 544,047 | 0.0% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $24.4K | 900,000 | 0.0% |
| Schrodinger Inc(SDGR) | COM | 80810D103 | $24.4K | 700,000 | 0.0% |
| Praxis Precision Medicines I | COM | 74006W108 | $23.6K | 1,200,000 | 0.0% |
| Atara Biotherapeutics Inc(ATRAGBX) | COM | 046513107 | $23.6K | 1,500,000 | 0.0% |